PocketEdge
← All news

Desk note · industry · Pharmaceuticals / exports

Strides Pharma earned more from outside the US than from America this quarter

Strides Pharma Science Ltd said on 1 November 2026 that revenue from markets outside the United States reached ₹6,963 million in the September 2026 quarter, exceeding US revenue of ₹6,855 million for the first time, with ex-US sales up 31% year on year while US sales rose 9%.

1 Nov 2026 · 2 min read

Key takeaways

  • •Ex-US revenue grew 31% year on year to ₹6,963 million in Q2 FY27, surpassing US revenue of ₹6,855 million, which grew 9%.
  • •Consolidated revenue rose 17.1% to ₹14,297 million; EBITDA reached a record ₹2,509 million though margin eased to 17.6% as input and freight costs climbed.
  • •The company launched three products in the US during the quarter while management flagged higher inventory and a longer cash cycle that added net debt in the first half.

What's going on here?

Strides Pharma Science Ltd released results for the quarter ended 30 September 2026 on 1 November 2026. The Bengaluru-based drug maker said consolidated revenue increased 17.1% year on year to ₹14,297 million. For the first time, its ex-US business was larger than the US in a single quarter: markets outside America contributed ₹6,963 million, up 31%, while the US brought in ₹6,855 million, up 9%. EBITDA hit a company record of ₹2,509 million, an 8.4% increase, but margin slipped to 17.6% from 19% as raw materials, freight, and operating costs rose. Strides launched three products in the US during the quarter and appointed Biren Gabhawala as an independent director. Management also noted higher inventory holdings and a longer cash-to-cash cycle that pushed net debt up by about ₹2,114 million in the first half of the financial year.

What does this mean?

Indian generics makers built scale in US oral solids first because pricing transparency and volume made the market attractive. When US growth slows or costs rise, diversified geographies matter. A 31% ex-US jump shows Strides is leaning on Europe, Latin America, and other regulated or semi-regulated markets where tender wins and distributor partnerships can offset US price erosion. Surpassing US revenue in one quarter is a milestone, not a permanent flip, but it signals the portfolio is less single-market dependent. Margin pressure from inputs shows that even record EBITDA can feel thin if freight and API inflation outrun price increases. Working-capital stretch warns that chasing growth can tie up cash before it shows up in PAT.

Why should I care?

If you supply APIs or packaging to Strides, ex-US momentum may mean more multi-country batches and shorter planning cycles. Hospital procurement teams outside the US may see additional generic entrants where Strides wins tenders. Investors comparing Indian pharma names should track whether ex-US outperformance repeats without further margin sacrifice. Lenders should watch whether management’s expectation of stabilising net debt by year-end holds. Follow the next two quarters for US launch contributions, ex-US tender pipelines, and any inventory normalisation commentary on the earnings call.

More desk notes

Disclaimer

For informational purposes only. Not investment advice. Verify with filings and a licensed adviser.